Side-by-side comparison of AI visibility scores, market position, and capabilities
World's most recognized Mexican beer brand distributed by Constellation Brands in US; $7B+ annual sales with beach lifestyle positioning among the fastest-growing import beer brands.
Corona (Grupo Modelo's Corona Extra) is the world's most recognized Mexican beer brand and one of the top-selling beer brands globally, known for its clear bottle, lime-wedge serving tradition, and "Find Your Beach" beach/lifestyle marketing that has established it as an aspirational leisure beer. Corona Extra is brewed and distributed by Grupo Modelo, which was acquired by AB InBev (Anheuser-Busch InBev) in 2013 for $20.1 billion. In the United States — Corona's largest market — the brand is distributed by Constellation Brands (NYSE: STZ), which holds perpetual rights to the Corona brand for US distribution.\n\nCorona's brand architecture includes Corona Extra (the flagship), Corona Light (reduced calorie), Corona Premier (lower carb/calorie premium), and Corona Hard Seltzer (launched 2020 to compete in the seltzer category). The brand's beach lifestyle association — reinforced through the iconic beachside advertising imagery and lime customization ritual — has made it a premium import despite being an accessible price point, competing in the "above premium" mainstream import segment rather than craft beer.\n\nIn 2025, Corona is Constellation Brands' primary revenue driver in the US beer segment, generating approximately $7+ billion in annual net sales. The brand continues to outperform the broader beer category as one of the fastest-growing import beer brands in the US. Constellation's 2025 strategy focuses on Corona's ongoing premiumization (Corona Premier and Cero non-alcoholic growing faster than Extra), expanding Corona Hard Seltzer, and growing the brand among Hispanic consumers who are the core demographic driving above-average beer consumption growth. Corona competes with Modelo Especial (its AB InBev sibling, distributed by Constellation), Heineken, and domestic premiums for the above-mainstream beer consumer.
Global pharma company with $55B 2024 revenue; successfully diversifying beyond Humira with Skyrizi, Rinvoq, and $8.7B Cerevel neuroscience acquisition.
AbbVie is a global research-based biopharmaceutical company focused on developing treatments for complex and serious diseases including immunology, oncology, neuroscience, aesthetics, and eye care. Spun off from Abbott Laboratories in 2013 and headquartered in North Chicago, Illinois, AbbVie rapidly became one of the world's top pharmaceutical companies on the strength of Humira — the world's best-selling drug for over a decade with peak annual sales exceeding $20 billion. AbbVie is listed on the NYSE and is a component of the S&P 500 and Dow Jones Industrial Average.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.